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Indices of Potential Lead Hazard
by Herbert S. Posner*
This review is concerned with the concentrations of lead in human whole blood, erythrocytes, plasma,
serum, softtissues, bone, and urine. The extent to which redistribution ofsome ofthe bound lead occurs is
outlined. The effects oflead on enzyme activities and on the accumulation ofmetabolic intermediates in the
blood and urine are described. A briefsection dealswiththe rangeofsignsandsymptoms thatcanoccurand
differences seen between symptomatic children and adults.
The issue here is the assay for individual and
group health hazards due to lead as assessed by
biochemical methods on body fluids and tissues.
These are "indices" of lead hazard but might also
be considered "sentinels," in that they attempt to
guard the gate appropriately, by allowing effects not
particularly hazardous to pass while calling atten-
tion to more reasonable hazards. Some other terms
used are also discussed. This range ofeffects partly
overlaps the one for which the term "subclinical
effects" (1) has been used. When some of the latter
are detected, they are hard to relate in a proven
manner, individually, to lead owing to their subjec-
tive and nonspecific natures.
As an early line ofdefense, therefore, we are de-
pendent mainly upon assay for the lead concen-
tration in body fluids, enzyme activities, the pres-
ence of abnormal concentrations of some metabolic
intermediates, and if possible, the evidence of lead
exposure. Signs and symptoms are, ofcourse, con-
siderably used in practice along with some of these
assays.
The review is part of a consideration of vehicular
lead emission as it contributes to the hazards oflead
(24).
Terminology
The use ofthe term "normal" or "normal value"
is often abused. For this reason, the distinctions
between "normal," "reference" and "discrimina-
tion" or "decisive values" will be considered gen-
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erally first, then specifically with regard to lead
hazard. The general part of this section owes much
to an editorial by Sunderman (7).
The usefulness of the term "normal value" var-
ies. Its accuracy is compromised by a poor correla-
tion between values in and outside the normal range
with the presence or absence of observed signs and
symptoms. This poor correlation can be due to the
following somewhat overlapping causes: (a) the oc-
currence of transient and wide fluctuations in val-
ues unassociated with clinical change, for example,
due to ingestion or inhalation of a substance fol-
lowed by its relatively rapid uptake and clearance
from the blood; (b) insufficient specificity ofthe test
for the component being tested; (c) poor correlation
between the value in the tested body fluid and the
degree of involvement of receptor sites-
structurally, quantitatively or over time; (d) bet-
ter correlation with a subfraction of the fluid, for
example, with plasma or serum, or with another
body fluid, for example, spinal fluid, or with con-
centration in a particular organ; or (e) the require-
ment for a prolonged period before the symptoms
become manifest.
Furthermore, there are three logical ambiguities
in the use of the word "normal": (a) ambiguity in
context-it connotes healthy in the clinical sense,
Gaussian in the statistical sense, and either ideal,
conventional, or habitual in the popular sense; (b)
circular reasoning-a "normal" population is one
which is, overall, free ofa condition while the pres-
ence ofdifferences from this group defines, overall,
the presence of the condition; and (c) emotional
connotations-what is "normal" is acceptable
while the "abnormal" is hazardous or frankly
harmful and should be corrected. It would be sur-
prising, however, if the terms normal value and
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future. An attempt is being made to encourage the
use ofmore accurate terms.
The use of "reference values" and "reference
intervals" is being fostered in Europe and North
America. As an example, 97 and 100lF (36.1 and
37.8°C) might be reference values for two individu-
als or two groups without clinical evidence of dis-
ease, while this variation from 98.6°F (37°C) could
be indicative of disease in others. The reference
value is a function ofthe following: (a) the vitae ofa
reference population; (b) external and internal con-
ditions of the collection of the specimen; (c) the
analytic method used along with both its precision
and accuracy; (d) the statistical tests used.
The terms "discrimination value" and "decisive
value" are even more specific. These are claimed
(8) to be the "best dividing lines between the 'nor-
mal' and the 'diseased' or between 'those who need
not be investigated further' and 'those who do.' " It
is often not possible to obtain this degree of
specificity with a single test. However, two or more
tests can frequently be used to distinguish between
the groups of individuals that are "normal" and
"diseased," or that "need not be investigated
further" and '"those who do."
Sunderman (7) lists the factors for the determi-
nation of a "discrimination value" as: (a) a clear
definition of the disease, (b) clear demarcation of
the stage to be specified by the test, (c) ability to
detect a high proportion oftrue positives, (d) ability
to eliminate other conditions (a low rate of false
positives), (e) knowledge of the prevalence of the
disease, and (f) consideration of the risk to the pa-
tient ofa positive ornegative misdiagnosis.
Specifically, when referring to a "normal" value
for whole blood lead (PbB), it is more reasonable
that a variety of reference values and reference in-
tervals (or ranges) exist for the groups of infants,
children, and adults of both sexes and also for dif-
ferent geographic populations and occupational
groups.
Waldron (9) recognized the problem of referring
to a normal value or a normal range for PbB and
offered the following thoughts. "A more valid ap-
proach would be for each center to establish its own
reference values taking into account such factors as
diurnal and seasonal variations (10-13) and then to
match the results against those for the appropriate
reference population. The results could then be ex-
pressed either in terms of standard deviations from
the mean or as an age-race-sex specific percentile
such as Elveback (14) has described. Used in this
way, blood lead estimations would alert the physi-
cian or environmental hygienist to an unrecognized
source of contamination while at the same time
serving as valuable corroborative evidence of ex-
cessive exposure in suspected cases ofpoisoning."
Chisolm (15) wrote, with regard to PbB determi-
nations, that "difficulties arise . . . when one at-
tempts to use this indicator [PbB] of group
exposures as a diagnostic indicator of toxicity.
There is a lively debate in the current literature
concerning the choice and interpretation of various
diagnostic tests for monitoring individuals who are
at risk" (Chisolm's italics).
He discussed the use of new definitions of the
terms "critical" and "subcritical effects," and
"critical site." Critical effect and critical site were
developed originally in the field of radiation biol-
ogy; now, as agreed upon by a Subcommittee on the
Toxicology ofMetals (16), the term "critical effect"
has been adapted "for metals such as lead . . .[as]
. . .the most sensitive and specific biologic change
beyond acceptable physiologic variation which is
caused by the metal (17). Although different effects
may be produced by a metal, the 'critical effect' is
the first measurable adverse effect not necessarily
the most serious one. 'Subcritical effects' are
measurable biologic changes which do not impair
cellular function." "Adverse" and "impair" ap-
pear to be equivalent. While neither the meaning of
adverse nor the distinctions between impaired and
not impaired are competely clear, Chisolm clearly
means that there is an operational, if not an actual
difference upon which we proceed. Unequivocal
distinctions are difficult, if not impossible, to define
and describe, for example, what we may consider
serious or nonserious at one time can, with new
data or an acceptable new interpretation, be ac-
cepted in an alternate manner. The last paragraph
of this section also applies.
"The 'critical site' is the location in the body
where the 'critical effect' occurs; it may be a sys-
tem, organ, cell type or cell component. . . . This
approach has advantages from the viewpoint of
preventive medicine. Intervention on the basis of
first or 'critical effects' at an early reversible stage
should prevent the occurrence of later adverse ef-
fects that may have serious consequences from the
clinical viewpoint." And then, specifically for inor-
ganic lead, "derangement of hemoglobin synthesis
in the erthyroid cells of the bone marrow is the
'critical effect' " (16, 18). . . . Decreased ALAD
[8-aminolevulinic acid dehydrase] activity, as
measured in vitro in mature red cells in peripheral
blood, is considered a 'subcritical effect' (16)
though it is a highly useful indirect indicator of ex-
posure (19, 20)."
In another vein, when it is determined that a PbB
value for an individual or group is outside its refer-
ence interval, this concentration, alone, does not
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For this reason we next would consider the enzyme
assays and product accumulations as well as the
signs and symptoms.
A variety of conditions can affect the values as-
sayed. For example, most of the lead in blood is
associated with the erthyrocytes. Because the
proportion of erythrocytes in blood normally fol-
lows a complex curve from the prenatal period
through puberty, a correction for hematocrit (Hct)
was proposed. Thus, before birth and until about I
mo of age the Hct is greater than in adults; it de-
creases below the adult male and female levels by
1-2 yr, and then rises slowly to the adult levels by
the teen years (21). Hct also varies with several
disease conditions. A decreased Hct is sometimes
seen with evidence of moderate or higher levels of
lead absorption. Correction for the Hct has been
controversial (22-28) and has not been generally
applied. It is discussed further in the next section.
In some cases, for example at very high PbB con-
centrations when plasma lead is increased, or when
studying effects directly on the erythrocytes, the
correction would be appropriate in order to obtain
the most accurate PbB values.
The "normal concentration range" for PbB in
humans has been reported extensively. All deter-
minations were not, obviously, made with the same
degree ofprecision or accuracy, and much has been
written about inter- and intralaboratory variations.
Lauwerys et al. (9) summarized a study that in-
volved 66 European laboratories in the analysis of
lead, mercury, and cadmium, and referred to earlier
comparative studies.*
They wrote, "the variability of the results is not
attributable to the use of different analytical
methods" [the three methods used most for the
lead were flame and flameless atomic absorption
spectrometry and colorimetry; two others were po-
larography and anodic stripping] "or difference in ex-
perience, because precise results were obtained by
laboratories using different techniques and having
different degrees of experience." However, only
*The following samples went to all laboratories: four aliquots
ofhuman urine A, three ofB; four aliquots ofcow blood C, three
of D; one sample of human blood E; three aliquots of aqueous
solution 1, one of2 (where 2 was an 0.1 dilution of 1). Fifty to 55
laboratories analyzed the blood and 33 to 34 the urines, for the
lead. The mean PbB for human blood (1.5 1 pooled from four
donors who were not occupationally exposed to heavy metals)
was 23.3 ,ug/100 ml (median of 18.1 and range of 1-115 Ag/1t00
ml). The range was not as startlingly large in the other biologic
and aqueous samples, 8.5- to 32-fold. The range includes both
the "precise" and "imprecise" laboratories. When the "pre-
cise" laboratories only were considered, the interlaboratory
coefficient ofvariation was still unacceptably large.
42-65% ofthe laboratories were "precise," i.e., had
a demonstrated "true" interlaboratory coefficient
of variation (CVo) of 10%. "Furthermore, . . .
the laboratories that measure the metals with preci-
sion do not exhibit the same degree of accuracy.
Heavy metal concentrations in blood and urine
cannot therefore be directly compared when the
measurements are performed by different
laboratories, even when the respective precisions
. . . are satisfactory." However, with an assured
standardization technique, the results of different
laboratories would be comparable. "It appears that
systematic errors are responsible for the high inter-
laboratory variation. . . . Further standardization
of their methods in order to reduce . . . systematic
differences [are necessary]. However, meaningful
relative comparison of different 'at-risk' groups re-
mains possible when all the analyses . . . in biologic
material are performed by the same [precise]
laboratory."
Other than for the imprecise analyses, differ-
ences in accuracy may also be partly a function of
the low concentration of lead and the ease of con-
tamination during collection, transportation or
assay. To protect against some of these problems,
when a PbB concentration appears increased, a
second specimen should be drawn and reanalyzed.
Last, it should be kept in mind that hazards are
not only in the short range. These can become man-
ifest: (a) at the time of assay or shortly thereafter,
(b) in the future, either because of a prolonged time
period before smaller detriments accumulate, (c) be-
cause cell differentiation has been affected and the
sequelae become evident only after differentiation
is well advanced, or (d) because of accumulation of
lead in blood components and in soft and hard tis-
sues, from all of which it is, at least potentially,
available for release and uptake by sensitive tis-
sues. Release from these sites is discussed below.
Lead in Blood and Urine,
Tissues, and Bone
Whole Blood and Urine
Whole blood lead (PbB) concentration has been
the most widely used test to monitor for a potential
lead hazard. However, its diagnostic value at the
borderline of hazardous conditions is quite limited.
It has been found that PbB is more a measure of
very recent exposure (30-33) than of total body
burden, and most lead in the body is within the hard
and soft tissues (33-36). Below are some of the best
data for "normal" concentrations ofPbB.
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concentrations of lead in whole blood (PbB) and
urine (PbU on 150 ml ofurine from a 24-hrcollection)
for over 800 specimens from 16 countries, including
New Guinea (aborigine population) and the U. S.
The subjects were mainly hospital employees or
clinic patients of both sexes and were screened to
eliminate those with unusual exposures to lead.
Chemically clean glass orpolyethylene bottles were
used for the samples which were then mailed to a
single laboratory in the U. S. for analysis by a stan-
dard dithizone method.
They defined "normal" as "the amount found in
persons who have had no evident occupational,
medicinal, or other unusual sources of exposure."
The "normal range" found was about 5-40 ,ug/100
ml,t but the values obtained included 45, 50, 53, 60,
and 100 (New York City) ,ug/100 ml with, in all
likelihood, more values in the latter range. The dis-
tribution was skewed as seen by the low median (18
,g/100 ml) and mean (17 ,ug/100 ml). For about 95%
ofthe tests the values were -40,g/100 ml.
Goldwater and Hoover (37) referred to a com-
prehensive review ofthe world literature by Stopps,
presented at a meeting (38) also referred to by
Stopps, et al. (39) and reproduced partly elsewhere
(40), which yielded similar as well as slightly higher
values for PbB between 1941 and 1965 and higher
values in some cases between 1931 and 1940 (Fig.
1). The assays of PbU are shown for comparison.
McLaughlin and Stopps (41) have determined PbB
and PbU, respectively, in 420 and 3819 employees
of E. 1. duPont de Nemours & Co. who were not
working with lead products, at 23 locations in the
U. S. and analyzed the data for nonsmokers vs.
smokers. Mean PbB values were: nonsmokers, 19.1
,4g/100 ml; cigarette smokers, 19.9 ,g/100 ml; other
smokers 17.3 ,g/100 ml. The values were not sig-
nificantly different. However, PbU was said to be
significantly (very slightly) less in the nonsmokers
than in the two other groups; 27.1 vs. 28.6 and 29.0
tThere are three corrections in the Goldwater and Hoover
report (37). The corrected values are given in the text and the
justification here. (a) From the data, the normal range of PbB
values is 5-40 rather than (5-40,ug/l00 ml. (b) To be consistent
with the paragraph directly above this in their report and also
with two values given in theirSummary and Conclusions, 95% of
the blood lead values rather than 98% was meant. And most
importantly, (c) the mean plus two standard deviations (2SD)
would give 40 rather than 50 ,ug/100 ml as the value that includes
95% ofthe blood lead values; 3 SD would yield 99o ofthe values
up to 50 ,ug/l00 ml. The interpretation (c) is consistent with the
paragraph above in their report where 95% ofthe PbU values are
included in 2 SD (about 65 ,ig/l00 ml). Dr. Goldwater concurs
with these corrections (personal communication).
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FIGURE 1. Concentrations of lead: (top) in whole blood lead
(PbB), reported in studies from 1931 to 1965); (bottom) in
urine (PbU), reported in studies from 1923 to 1965. Data from
Stopps (40) with permission.
,ug/100 ml, respectively. They quote several other
studies of smokers and nonsmokers that had
slightly different results. Thus, in one study, 21
,ug/100 ml was found in smokers and 16 ,ug/100 ml in
nonsmokers, while another found 16.4 and 16.3
,ug/l00 ml, respectively.
Butt et al. (42) reported the mean PbB value for
47 presumably normal hospital employees to be
17.7 + 0.8 (SE) ug/100 ml.
Robinson et al. (43) reported blood lead data for
103 children of ages 5 hr to 13 yr, where there was
normal temperature and no history ofpica or previ-
ous lead poisoning or symptoms suggestive of lead
poisoning. The values for nine neonates ranged
from 7 to 28 Ag/l00 ml; for 28 infants up to 6 mo of
age and including the neonates, 5-31 ,ug/l00 ml (me-
dian, 15 ,ug/100 ml); for 75 children between 6 mo
and 13 yr, 3-54 ,ug/100 ml (median, 27 ,ug/l00 ml,
with 90% of the values between 15 and 40 Ag/l00
ml). The difference between the values for infants
less than 6 mo and children 6 mo to 13 yr was statis-
tically significant. The 6 mo to 13 yr values were
pooled for statistical analysis since there was no
difference between those 6 mo to 4 yr and 4 yr to 13
yr. All values were shown on a scattergram.
Erythrocytes, Soft Tissues, and Bones
At least 90% of the lead in blood is generally
associated (24, 43, 44) with the erythrocytes (PbE).
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264In in vitro tests, lead is transferred rather quickly
from the plasma to erythrocytes (45, 46). At low
PbB values and under some other conditions, as
noted below, the plasma and serum contain a higher
percentage or an additional amount of lead. There
are at least two erthrocyte compartments for the
lead, one associated with the membrane and the
other within the cell (46). The lead is more easily
displaced from the membrane and displaced with
more difficulty from inside the cell (46-48). While
some believe that the erthrocytes are mainly an in-
active transport and storage site for the lead (24,
27), others suggest that uptake by the erythrocytes
may not be quite so benign (26). Some of the differ-
ence ofopinion, however, is due to definition.
Angle and Mclntire (23) point out that, assuming
90% of PbB is in the erythrocytes, at a Hct of45%,
a 20 ,ug/100 ml PbB concentration would mean PbE
was 40 Ag/l00 ml; at 35% Hct, PbE would be 85
Ag/100 ml. Stretching this further (26), at a Hct of
45% and PbB of 40 ,ug/100 ml, PbE would be 85
,ug/100 ml; at 30% Hct, it would be 160 ,ug/l00 ml.
Hct values of 25-30% have been reported for 42
children at PbB concentrations of70-136 Ag/l00 ml
(24). The higher concentrations in the erythrocytes,
therefore, in the anemic condition, may represent
an additional burden to normal development or
functioning of the erythrocytes. Evidence to sup-
port the contention was presented (23, 26). How-
ever, the higher concentrations in the erythrocytes
may not have a relationship to the effects oflead on
the nervous system, kidney or other tissues (25).
While the reductions ofhemoglobin (Hb), Hct, and
erythrocyte count can occur with lead absorption,
they are not generally associated with the early
stages of toxicity or with PbB values up to at least
50 ,g/100 ml, unless there has been a previous
chronic exposure at perhaps higher levels. The
mechanisms by which the effects on erythrocytes
come about are complex and include the inhibition
of Hb synthesis (both the heme and globin
moieties), abnormal erythrocyte production, and
crenation and fragility of the erythrocytes leading
to hemolysis. Basophilic stippling is well known in
lead toxicity but it is also caused by many other
conditions. The percentage of reticulocytes is
sometimes increased (28, 49-52).
Maxfield et al. (53) found a slight increase of Hb,
Hct, and the erythrocyte count in dogs fed lead
acetate along with their diet. The lead acetate was
fed at 100 ppm and also at 500 then 1000 ppm for 46
wk. They mention studies by Cantarow and
Trumper (54) and Pecora et al. (55). [the latter
quoted by Waldron (56)] that suggest that at low
lead concentrations, the lead appears to stimulate
erythropoiesis. The mechanism by which this oc-
curs was suggested to be, perhaps, as secondary to
either hypoxia or hemolysis. Maxfield et al. (53)
also could not find interference with the recovery
rates for Hb, Hct, or erythrocyte count in dogs
after the dogs had been bled in two stages to pro-
duce 30-40% reductions of these three erythrocyte
parameters. However, alternate results were ob-
tained in the baboon by Kneip et al. (57) and in the
rat by Gelman and Bus (58).
Rosen et al. (24) assayed Hct in 135 children with
PbB of 20-136 ,ug/100 ml. In the two groups with
PbB of 20-29 and 30-39 ,ug/l00 ml, mean Hct was
36%; at 40-49 and 50-59 ,g/ml it was 34%; at 60-69
,ug/100 ml it was 33%. . . and at 100-136 ,mg/100 ml
it was 26%.
Lead is also taken up by soft tissues and by bone.
Much has been written about these sites of lead
accumulation. Some recent studies of the concen-
trations attained in soft tissues and bone are by
Gross et al. (34), Barry (35), and Poklis and Frei-
muth (36). The data were analyzed as a function of
age, sex, occupation, and geographic location.
Rabinowitz et al. (33) studied lead under dy-
namic conditions at physiologic concentrations in
five healthy men with the stable isotope, 204Pb. The
data obtained could be explained on the basis of a
three-compartment model, though it is more likely
that there are many compartments (pools). The first
pool is the blood. It contained 1.7-2.0 mg of lead in
the five subjects and had lifetimes of 27-40 (mean
35) days. This pool is in direct communication with
ingested lead, PbU, and the second and third pools.
Since the mean lifetime in pool one was 35 days and
the mean lifetime oferythrocytes is 110-120 days, it
is inferred that lead enters and leaves the erythro-
cytes several times during the erythrocyte lifetime.
This study supports the finding of Butt et al. (42).
The second pool consists mainly of soft tissues.
It contained 0.3-0.9 mg oflead and had lifetimes of
30-55 days in three individuals. It includes the hair,
nails, sweat, and salivary, gastric, pancreatic, and
biliary secretions. The total for these two pools is
about 3 mg. This is less than the total of 10-30 mg
found in soft tissue at autopsy by Schioeder and
Tipton (59) and the 9.3 mg mean in nonoccupation-
ally exposed men, the 15.7 mg in men with occupa-
tional exposure, and the 6.2 mg in women, found by
Barry (35).
The third pool is mainly the skeleton and contains
most ofthe lead in the body. Gross, et al. (34) esti-
mated 200 mg of lead in the body, and Barry (35)
reported mean values in men of 165 mg total lead
without occupational exposure, 522 mg with occu-
pational exposure, and 119 mg in women. On the
whole, lead has a very long lifetime in the skeleton.
Although the 2114Pb entered both the dense cortex
August 1977 265and spongy trabecular bone, a more rapid turnover
occurs in the trabecular bone, as seen by the two- to
threefold greater ratio of 204Pb to total lead com-
pared to the cortex.
On a comparative basis, Rabinowitz et al. (33)
point out that their results in humans differ from
those reported for the rat and hamster. When rats
and hamsters inhaled radioactive lead, lead ac-
cumulated in the erythrocytes only to about halfthe
extent, there was more found in the kidneys, and
clearance from the blood was more rapid (60). In
another study, rats were given a trace amount of
210Pb in 25-250 gg of carrier by single intravenous
injection, an amount which may have altered the
normal handling of lead and also erythrocyte survi-
val time. More lead then occurred in the feces and
also transferred to the skeleton, while again it was
cleared more rapidly from the blood than in humans
(61, 62).
There is great interest in conditions that affect
release, redistribution and excretion of lead from
erythrocytes, soft tissues and the bones. Under
some circumstances, for example, satisfactory che-
lation therapy, beneficial results occur; in other cir-
cumstances, toxic episodes have either been re-
ported or suggested.
The lead of erythrocytes occurs both within the
cells and in association with the membrane in a ratio
of 9:1 (63). Within the cell it is bound to hemoglo-
bin, to a colorless component with molecular
weight ofabout 10,000 and to other lower molecular
weight components (64), perhaps phosphate (45),
2,3-diphosphoglycerate (23), and others (27). Hu-
man erythrocytes appear to be saturable with lead
in vitro only at concentrations greater than 200
,ug/l00 ml PbB. Thus, only above this concentra-
tion did an increasing amount of lead remain in the
plasma following centrifugation (46). Rosen et al.
(24) found a similar relationship in vivo in children,
in which case the plasma concentration remained
constant up to a PbB value of 136 ,ug/100 ml. Higher
PbB concentrations than these have been found in
occupationally exposed workers, usually with little
lead occurring in the plasma (65).
The incubation of rabbit erythrocytes with 203Pb
(64) showed that 94% ofthe isotope was taken up in
1 hr. This uptake was inhibited in a dose-dependent
manner by nonradioactive lead and more so by
Fe3+ as well as Fe2+ and Imferon, a parenteral
Fe3- preparation. Of the three 203Pb components
separable by Sephadex chromatography of
hemolyzates-Hb, a component with molecular
weight about 10,000 and a small molecular weight
component-only 203Pb in the smallest component
decreased upon the addition of Fe. Incubation with
Ca, Mg, Cu, Hg, Zn, Co, Ni, and Cr did not have
the effect of Fe. The rabbits then received Fe in
saline, in l ivo, at 4 mg/kg or saline alone, in each
case 1 hr before administration of 203Pb. At 1 hr
after FE, only 21.6% of 203Pb was taken up by the
erythrocytes, while after saline 95.6% was taken
up. Various aspects of the roles of iron deficiency
and iron deficiency anemia for the hazard of lead
was discussed in the report.
Human erythrocytes equilibrated with lead for 6
or 24 hr lose lead, on addition of CaNa2EDTA,
more slowly than comparable erythrocytes equili-
brated for only 15 min. It appears that the lead
transfers from a more easily accessible or weakly
bound site, to a site where it is less accessible or
more tightly bound (46).
Rosen and Haymovits (66) collected erythrocytes
from rats treated with lead and suspended these in
solution with CaCl., at Ca2+ concentrations of 0, 2,
4, 6, and 8 mg/100 ml. The mixtures were incubated
for 15-30 min. PbE decreased by 0, 0, 12, 24, and
40%, respectively, within the 15-min period. At
preincubation PbE values of <50, 51-99, and
100-180 ,Ag/l00 ml, release of lead by Ca2+ was,
respectively, negligible, 15%, and 38%, indicating
that only above a threshold PbE concentration
could lead be displaced (67).
Forced entry of Ca2+ into the erythrocytes was
then achieved by addition of A23187, a compound
that reacts with Ca2+ to form a lippophilic complex
(47). At suboptimal Ca2+ concentrations, greater
displacement of lead then occurred, though at opti-
mal concentrations there was no further displace-
ment. Rosen and Haymovits suggested that a larger
displaceable fraction is on the surface of the eryth-
rocytes while a smaller but also displaceable frac-
tion was either within or below the membrane.
In six lead-intoxicated children, the concentra-
tion of Ca2+ in serum increased by 1.50 + 0.2 (SE)
mg/100 ml above the baseline during chelation
therapy with CaNa2EDTA. The increase closely
paralleled the decrease of PbB. Furthermore, the
subsequent decrease of Ca2+ in the serum to
baseline coincided with the increase of PbB shortly
after EDTA therapy was terminated. It was sug-
gested that a portion of the EDTA effect in these
children resulted from the Ca2+ that was coadminis-
tered with EDTA (48).
There have been many explanations offered con-
cerning why one individual develops symptoms and
another not, and what causes periodic exacerba-
tions and then subsiding symptomology. These in-
clude: (a) the differential availabilities of "diffusa-
ble" lead vs. lead that is stored at more inaccessible
sites, (b) recent high dose vs. more chronic expos-
ure and accumulation, which may operate through
the principles of differential accessibility, (c) an in-
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from the gastrointestinal tract, (d) physiologic
"trigger" mechanisms such as parathyroid,
thyroid, or calcium effects (among others), that
could mobilize stored lead particularly in bone, but
perhaps also in erythrocytes or soft tissues, (e) in-
advertent mobilization oflead by transient acidosis,
febrile conditions, dietary components, and
perhaps some drugs, and (f) an increase in the
concentration of plasma or serum lead. Goyer and
Mahaffey (68) wrote of differential effects some-
times seen in association with age, season, calcium
and phosphorus imbalances, iron deficiency, pro-
tein, vitamin D, ascorbic acid, nicotinic acid, al-
cohol, other metals, coexistent diseases, and with
the formation of intracellular inclusion bodies.
Sorell etal. (69) alsodiscussed some ofthese.
Early techniques for therapy attempted to im-
mobilize the lead by using conditions that would
make it either less soluble or more easily deposited
in bone (70). More frequently and at present, the
removal of diffusable lead or stored lead is at-
tempted under conditions that try to avoid the de-
velopment orexacerbation ofsymptoms.
Since it has become somewhat common to treat
children with moderately high PbB concentrations
with chelating agents in an attempt to avoid appar-
ently more subtle lead hazards, reasons for a gen-
eral avoidance of pharmacologic de-leading have
also been presented. In its place, there would be an
aggressive lead screening and treatment program,
conducted by a nurse practitioner in a family-
focused neighborhood health center (71). In this
study, it eventually became necessary to treat six of
the children with CaNa2EDTA because ofa break-
down of the lead hazard abatement program, pica
by the children, ages less than 3 yr and a rapidly
increasing PbB concentration within 2-3 mo (from
40-50 ,ug/100 ml to 60-80 ,g/100 ml). However, 31
children in this study were not treated by chelation.
Rather, PbB was decreased over a 7-mo period by
natural clearance mechanisms and with the aid of
elimination of lead from the environment and be-
havior techniques. The peak mean PbB concentra-
tion in the untreated group was 55 ug/100 ml, and
the highest single value was 76 ,g/100 ml. These 31
children were chosen for intensive follow-up that
lasted 18 mo because their PbB concentrations
were more than 40 ug/100 ml for three successive
determinations. The argument is properly made,
that the medical need to bring about a rapid change
in the children and also to avoid undue stresses on
overworked medical and paramedical facilities must
be balanced against the psychic trauma often as-
sociated with hospitalization ofyoung children and
adverse reactions than can occur with the chelation
therapy.
In some attempts aimed at mobilization and re-
moval ofthe lead, PbB increased but the urinary or
fecal excretion oflead did not. When aconsiderably
increased excretion of lead occurs a portion of the
lead should derive from the more mobile fraction of
bone, since, especially in adults, the erythrocytes
and soft tissues contain only a very small portion of
the total body lead.
Some of the therapeutic regimens used to in-
crease the excretion of lead, or at the least remove
some "diffusable" lead, have included: low cal-
cium, high phosphorus diet (72), low calcium diet
with or without the coadministration ofNH.,Cl (72,
73) or H3PO., (73), Na2HPO., (74, 75), sodium or
potassium iodide (76, 77), sodium citrate (78), di-
mercaprol (2,3-dimercaptopropanol, BAL) (79-81),
penicillamine (81-83), and edathamil (calcium ver-
senate, CaNa2EDTA) (81-85).
Castellino and Aloj (86) and Hammond (87)
studied the removal of lead from body sites by
CaNa2EDTA. Castellino and Aloj (86) used rats.
They gave a dose of lead and showed that when
EDTA administration began 1 day later and con-
tinued daily, a rapid then a slower phase of lead
elimination from whole blood, erythrocytes, liver,
kidneys, lungs, and heart occurred. They suggested
that the EDTA removes extracellular lead (the
rapid phase), shifting the equilibrium concentra-
tions between the cellular and extracellular com-
partments, which is necessary for further elimina-
tion (the slower phase). Urinary excretion of the
lead increased while fecal excretion decreased.
When EDTA was begun 7 days after the lead, only
small quantities oflead were now released from the
same tissues; the urinary excretion increased while
fecal excretion remained the same. Lead in the
femur, as arepresentative ofbone, was notreleased
in eitherexperiment.
Hammond (87) used rats and rabbits. He first
treated the rats with CaNa2EDTA on days 4, 17,
34, and 60 after the lead. The concentrations oflead
that remained were then assayed in'aliquots ofnitric
acid digests of pooled bones, pooled soft tissues,
erythrocytes and pooled urine and feces. The
amount of lead released, as in the previous study
(86), decreased as the span increased between lead
and EDTA administration. Although the mobile
bone pool of lead was small when compared to the
total of the bone pool, this fraction was still much
greater than the mobile soft tissue pool. Because of
this relationship, bone was, quantitatively, the main
site for the lead released. It was suggested that the
analysis offemur only, by Castellino and Aloj (86),
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states of bone tissue. In the erythrocytes, the lead
concentration stabilized within 17 days and then
remained nearly constant.
Hammond (87) found that at various times after
EDTA administration there does not appear to be a
simple, constant relationship between the amount
of lead in soft tissues and the amount released by
EDTA. There was also nota constant proportional-
ity between the removal ofleadfrom the softtissues
and from the skeleton. Rabbits responded similarly.
Although bone may account quantitatively for
most body lead released by EDTA and both the
mobile and less mobile fractions oflead in bone are
still important with regard to secondary redistribu-
tions and potential hazards, it is presumably either,
or both, the "diffusable" and the more stable lead
in some of the soft tissues that accounts for the
symptoms oflead toxicity.
Jugo et al. (88) found that CaNa2EDTA adminis-
tered to 15-day and 18-wk-old rats after lead re-
sulted in a lesser excretion ofthe lead in young rats.
The same effect occurred with BAL as the chelat-
ing agent, and it was independent ofthe dose, route
and frequency ofadministration ofthe lead and also
of the molar ratio of chelating agent:metal. They
proposed that there may be a lower free lead or
active lead concentration in the young rat due to
greater binding strengths of the lead for tissue
ligands and cited supportive data from the work of
others.
In the statement on increased lead absorption and
lead poisoning in young children by the Center for
Disease Control (89) it is noted that "children who
require chelation therapy will also require long-term
medical surveillance and care. 'Rebound' of blood
lead levels resulting from release oflead from tissue
poolsafteranapparently successfulcourseofchelation
therapy should be anticipated."
rhe amount of "chelatable lead" in a carefully
controlled 24-hr urine sample can sometimes be a
better indicator of the "internal dose" oflead than
PbB (15). Provocative chelation, also referred to as
an EDTA mobilization test, has been used as a
diagnostic test in asymptomatic patients. In this
case there should be particular attention to the pos-
sible induction ofsymptoms (89).
An alteration in bone or teeth of binding, more
permanent deposition and the redistribution oflead
would be expected in association with a variety of
normal and clinical conditions, forexample: (a) dur-
ing early development, (b) continued growth at the
epiphyses until maturity, (c) conditions that involve
bone remodeling or resorption and (d) during preg-
nancy (69, 91-93). At these times, the lead may be
more mobile than in quiescent periods.
Analyses of the lead in different bones and in
different parts of the same bones (34, 35) and the
metabolic, compartmental studies of Rabinowitz et
al. (33, 90) show that bone is heterogeneous with
regard to the uptake and metabolism oflead. There
are both rather mobile and relatively stable com-
partments. EDTA in vivo, for example, will
mobilize some of the lead. It was suggested many
years ago that lead appears to follow calcium with
regard to the skeletal system and that factors that
affect the state ofbones would be expected to affect
its lead content (94).
Recently, Rosen and co-workers have been
studying the effects ofhormones and ions known to
affect bone. They have looked for the ability to alter
the lead content of bone in organ culture and have
worked with fetal rat bones. Pregnant rats were
given the normal isotope of Pb in drinking water
throughout gestation and then a dose of210Pb a day
before sacrifice. Rosen and Wexler (95) investi-
gated the effects of parathyroid hormone (PTH),
calcitonin (CT), inorganic phosphate (Pi), Ca, and
Mg onfetal radii and ulnae overa48-hrperiod.
They found that at a low concentration of Ca
(0.7mM), resorption occurred, and some of the
formerly deposited 2 0Pb was released. Addition of
PTH to the medium did not cause any further re-
lease and assay for total Pb in the control and
PTH-addition preparations showed similar
amounts of Pb. Heat treatment ofthe bones to stop
the metabolic activity of their cellular fraction
stopped the release of the 210Pb suggesting, though
not proving, that physicochemical exchange alone
was not involved. A high Ca concentration
(2.8mM), however, inhibited the release of 210Pb
due to PTH. With an intermediate amount of Ca
(1.4mM), the decrease of210Pb was proportional to
that of the total Pb, indicating that a selective ex-
change ofthe more recently acquired 210Pb was not
involved. Finally, the release of Ca from the bones
approximately followed the time course of release
ofPb.
An increase of Pi concentration (2mM) inhibited
the release of 210Pb in both the control and PTH-
addition preparations, but more so in the latter.
Increasing Pi further to 4mM inhibited the release
from each to an equal extent.
At a low concentration of Mg (0.4mM), PTH-
induced release was again inhibited more so than in
the control (non-PTH) preparation. At a high Mg
concentration (1.6mM), no effect was detected.
CT at a normal Pi concentration (1mM), reduced
the amount of 210Pb released to below that of the
control preparation. Increasing Pi to 2 and 4mM
further inhibited release and in an approximately
additive mannerwith the CT. Assay forthe total Pb
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the extra Pi were present.
In these experiments, the mobile Pb compart-
ment was about 20o of the total of 210Pb incorpo-
rated. It was stated, as an as yet unpublished ob-
servation, that both EDTA and increased culture
times of72 and 120 hr showed the mobile compart-
ment to be two- to threefold greater, and closer to
that found for Ca by others. They also tried to re-
late their findings to in vivo situations by reference to
the literature and to some oftheir own studies.
It is quite clear from the studies sampled in this
section and those cited elsewhere (96) that the
erythrocytes, soft tissues, and bones can be active
with regard to the turnover oflead within them due
to a variety ofconditions. Some sites are quite sta-
ble. However, many will turn overatleast aportion
of their lead in response to normal, inadvertent, or
purposeful influences.
Plasma and Serum
As noted, usually 90% or more of PbB is as-
sociated with the erythrocytes. Accurate assay of
the plasma (PbP) and serum lead (PbS) have been
more difficult because of the usual methodologic
difficulties and lowconcentrations.
However, there have been studies and comments
that indicate the PbP and PbS can be increased at
times. It has been assayed in greater amounts, for
example, in association with toxic symptoms (65, 97)
and with the use of CaNa2EDTA (86, 98) for the
purpose of de-leading individuals. However, the
PbE and noncell concentrations have also been in-
creased without apparent symptomology, and vice
versa. Toxicity has been attributed to a variety of
free and bound forms of the lead (on proteins or
smaller chelating molecules, inorganic molecules,
etc.) which would then be variably available for
transport through membranes.
PbP and PbS are in either rapid or more slowly
achieved equilibrium with essentially all body stor-
age sites (99). It is in closest proximity to both the
erythrocytes and to the most vascular tissues, less
so with immature and mature bone. The extra lead
appearing in the noncellularfraction ofblood could,
therefore, have several sources: (a) erythrocyte
damage and release, (b) nondamaging release from
erythrocyte-bound sites, (c) release from soft or
hard tissues, (d) the occurrence of a defect in the
erythrocyte or tissue uptake of either newly ab-
sorbed lead or ofthe reuptake oflead that has been
released from binding sites, or perhaps (e) all of
these, depending upon theparticular conditions.
In vitro studies concerning uptake and release
with isolated erythrocytes and inbone organculture
were reviewed in the previous section.
Bambach et al. (44) referred to nine reports in
which lead in the blood was suggested to be mainly
in the cells, four in which there was found a more
equal distribution with the plasma, and only one in
which it was the plasma that had most lead. In their
study, they found at least 90% in the cells ofrabbit
blood. This was the case even with PbB values up
to 140 and 290 ,ug/100 ml. They used the colorimet-
ric methodwith dithizone foranalysis.
Robinson et al. (43) reported PbP for 82 children,
apparently of ages 5 hr to 13 yr, with normal temp-
erature and no history ofpica, previous lead poison-
ing, or symptoms suggestive of lead poisoning.
They used a dithizone method. In 53 lead was not
detected, in 22 it was <9 ,ug/i00 ml, and in seven it
was >9 ug/100 ml. Since hemolysis was said to
occur to some extent in the seven latter cases, this
could accountfor atleastapart ofthe lead.
Butt et al. (42) reported serum lead concentra-
tions for three groups in the Los Angeles area. The
analysis was by emission spectrometry and it was
part ofa 15 element survey. With 122 blood donors,
the mean serum concentration was 3.9 + 0.2 (SE)
,ug/100 ml; with 96 patients hospitalized for elective
surgery or generally for a variety of degenerative
diseases, the mean was 2.7 + 0.5 ,ug/100 ml; and
with 48 normal employees ofthe hospital, the mean
was 2.8 + 0.3 ,ug/100 ml. In the second group, for7,
10, 9, 36, and 27 individuals, respectively, newborn,
ages 5-19, 20-29, 30-49, and 50-79, the mean serum
lead values were 6.5, 1.3, 2.6, 2.4, and 3.3 ug/100
ml. Standard errors were not given for these data. It
was said that the "metal serum levels were rather
uniform in all classifications such as age, race, sex,
orlength ofresidence in the Los Angeles area."
Farrelly and Pybus (100) analyzed serum lead by
atomic absorption spectrometry in a portion of the
individuals they studied who had either no unusual
exposure to lead or had varying exposures. They
were primarily interested in the packed red cell
concentrations. They stated that "even in cases of
lead toxicity, we find the serum lead to be less than
5 .g/100 ml." These data are not presented.
Rosen et al. (24, 48) determined plasma lead con-
centrations by flameless atomic absorption spec-
trometry for 165 children including: 13 newborns,
14 and 17 children, respectively, with "normal"
PbB values of 20-29 or 30-39 ,ug/100 ml; 8-24 chil-
dren in succeeding 10 pLg/100 ml PbB range groups
up to 90-99 ,ug/100 ml; 10 children in the 100-136
,ug/100 ml range; and 17 children with sickle cell
disease, who had PbB concentrations of 18-136
,ug/100 ml. The plasma lead concentration for each
group was between 1 and. 7 ,mg/100 ml, with the
mean concentrations 3.0-3.3 ug/100 ml.
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treatment also showed concentrations around 3.0
ggIlOO ml (personal communication). The two
groups with the highest PbB values (100-136 ,ug/100
ml and the children with sickle cell disease, 18-136
ug/l100 ml) included some children with en-
cephalopathy (48). However, the relationship ofthe
time of blood sampling to the occurrence of en-
cephalopathic symptoms was not mentioned, and
PbP was not determined during the chelation treat-
ment (Rosen, personal communication).
It is not uncommon to see asymptomatic children
in the presence of relatively high blood lead con-
centrations. In discussing the report by Rosen et al.
(24), Chisolm (25) remarks "whether plasma lead
concentration is measurably higher in symptomatic
cases remains obscure." In one of the reports (48)
some cases ofencephalopathy are referred to, in the
groups with PbB concentrations of 100-136 and
18-136 ,g/100 ml, while in their other report (24)
this notation was not made. Fluctuations of PbP on
an hourly basis cannot be ruled out and a potential
effect of the chelation therapy was not sought. In-
deed, Castellino and Aloj (86) state, "in the blood,
lead was mainly bound to the cells and more than
10% was found in the plasma only at the beginning
of the treatment with chelant" (CaNa2EDTA, in
the rat, no mention ofassociated symptomology).
Bessman and Layne (98) administered
CaNa2EDTA to two adults and three children and
determined either PbB or PbE along with PbP in
each case by means of a dithizone method. The
analyses were done prior to treatment and at 2, 4,
and 8 hr after treatment (Table 1). Prior to treat-
ment, PbB was above normal in patient 2 (61 ,ug/100
ml) and PbE and PbP were above normal in patient
3 (275 and 63 ,ug/l00 ml, respectively). The treat-
ment appeared to increase the lead concentration
Table 1. Effect ofCaNa2EDTA on plasma, erythrocyte, and whole
blood lead concentrations.a
Lead concn, ,ug/100 ml
After treatment
Age, Blood Before 2 4 8
Patient yr fraction treatment hr hr hr
1 Adult Erythrocytes 15 23 3
Plasma 2 17 19
2 Adult Whole blood 61 - 70 100
Plasma 0 - 27 48
3 3 Erythrocytes 275 186 68 34
Plasma 63 123 80 55
4 4 Erythrocytes 12 - 109
Plasma 0 - 139
5 5 Whole blood 7 12 10 12
Plasma 2 22 17 12
aData of Bessman and Layne (98).
for each parameter, but to different degrees and
over different time courses. The PbP concentration
increased in each case, to a considerable extent in
some ofthe patients (patient 2, 27 and 48 ,ug/l00 ml;
patient 3, 123, 80, and 55 ugIl/00 ml; patient 4, 139
,ug/100 ml). Bessman and Layne did not mention
whether or not there was associated symptomology
in these specific cases. An earlier report (84) de-
scribed the use of CaNa2EDTA during the acute
stage ofencephalopathy.
An early and extensive report by Smith et al. (97)
sought a relationship between PbS and the degree
of symptomology observed in those who had been
exposed industrially (24%), from paint (2%), by the
administration of lead colloid for cancer
chemotherapy (56%), from x-ray usage (1%) and in
an unknown manner (18%). Despite important
methodologic criticisms, including some aspects of
the assay for lead and the subjective nature ofmany
of the signs and symptoms, the study is worth not-
ing for comparison with other reports. The data
should be considered either semiquantitatively
(Table 2) orqualitatively (Table 3).
A dithizone method was used for lead assay. A
concentration of 10 ug/100 ml [the data were con-
verted from mg/10 g (taking 1 g = 1 ml) to be consis-
tent with most other reports] was said to be the
level at which the data should be-accepted "qualita-
tively rather than quantitatively." The study was
done in the same laboratories as the one by Wil-
loughby and Wilkins (101), a variant of whose
method was utilized. Willoughby and Wilkins (101)
also state that the error in the recovery of lead
added to cow blood and analyzedforPbB, was
- 10
gtg/100 ml for 41 of 42 samples when the lead was
added in quantities of 20-100 ,ug/100 ml. This
amount, then, is the lower limit for the analysis
though not for detection. An apparently rigorous
procedure was followed to avoid lead contamina-
tion ofglassware and hypodermic needles.
There was awareness of the need to "minimize
any changes in equilibrium of the serum and cell
lead" from their description of defibrination and
separation. They also referred to several reports to
support the use of serum instead of plasma on the
basis oftrying to avoid lead shifts from erythrocytes
to the serum. Bambach et al. (44) reported a few
years later than PbP and PbS concentrations did
not significantly differ despite the use of heparin,
citrate, oxalate or cooling in an ice bath for 1 min to
prevent clotting, or in serum, for rabbits who were
fed lead acetate. They suggested that this "indi-
cates that all these results can probably be com-
pared to those obtained by workers using the
serum-clot separation."
Smith et al. (97) cited many references to the
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sometimes seen in lead toxicity. If hemolysis oc-
curred in some samples, one would expect that it
would have been mentioned. However, there is no
mention of hemolysis or the exclusion of samples,
which is an improbable situation considering the
large number ofsamples and analyses. Some loss of
lead from the erythrocytes to the serum, cannot be
excluded. For the two groups of "normal" indi-
viduals, they note that "in no instance was lead
detected in the serum . .. by the analytical method
employed. This has been substantiated by Wil-
loughby and Wilkins in a recent series of patients
without signs or symptoms of plumbism." How-
ever, Willoughby and Wilkins (101) remark "of the
58 separated specimens, only six contained slightly
positive amounts oflead in the serum fraction, this
fraction from all other samples being found lead-
free. However, no significance can be attached to
these few positive serum lead values because each
was less than 0.001 mg [10 ,ug/100 ml], which is
within the limits of experimental error."
Finally, Smith et al. (97) state that "at the ap-
proach of death there are indications of a general
breakdown ofthe body's biological and physiologi-
cal equilibriums accompanied by aflood oflead into
the peripheral circulation which is neither elimi-
nated nor detoxified in the manner of the normally
functioning defense system. It is shown in Table 13
[of Smith et al.] that in cases of latent, mild, or
inactive plumbism, the distribution ofthe lead in the
serumr., cells + fibrinfraction and whole blood tends
to equalize each otherat, or shortly before death."
For 41 patients (Table 2) who had clearly present
signs and symptoms, PbS was 20-150 Ag/100 ml
(mean, 58 ,g/100 ml). For 25 of the 41 patients
(60%), PbS was from 50-100% thatfound for PbB.
For 35 patients with either acute oractive chronic
lead toxicity, but in whom the clinical signs and
symptoms were weak or temporarily absent, PbS
was 10-40 ,ug/100 ml (mean, 20,ug/100 ml). Foreight
of the 35 patients (22%), PbS was 50-100% of that
found for PbB.
For both ofthe above groups, the concentrations
oflead in the cells + fibrin and PbB fractions were
greater than for the comparable analyses ofthe two
"normal" groups shown in Tables 4 and 5 of Smith
et al.
For 18 individuals who were mainly 4 mo or more
past either an acute toxic reaction or the active
phase of chronic toxicity (in one case 2 mo), lead
was below the assayable level in the serum. For
these individuals also, the lead in the cells + fibrin
and PbB were greater than for "normal" groups
(Smith etal., Tables 4 and 5).
For the 36 "normal" individuals (doctors,
nurses, technicians, secretaries and one artist) and
47 patients hospitalized for nonlead-related
reasons, lead was below the assayable level
in serum. The mean concentrations of lead in
the cells + fibrin (62 and 67 ,g/100 ml) and PbB (36
and 33 ugI/100 ml) were higher than would be ob-
Table 2. Lead concentration in the serum, cells + flbrin and whole blood of five groups of lead-exposed
and "normal" individuals.'
Smith Concentration, gg/100 ml
et al. Concentration,_,ug/100_ml
Table No.; types of Cells + Whole
No. individuals Serum fibrin blood
9 41; acute and active phase of 20-150 50-510 50-280
chronic toxicity, with clearly (mean = 58) (mean = 152)b (mean = 109)b
present signs and symptoms
10 35; same as Table 9, but weak 10-40 30-370 20-180
or temporarily absent signs (mean = 20) (mean = 127)c (mean = 73)c
and symptoms
11 18; mainly 4 mo or more Nil 140-640 70-220
after acute or active (mean = 250)d (mean = 117)d
chronic episode
4 36; "normals" Nil 10-110 10-50
(mean = 62) (mean = 36)
5 47; hospitalized for nonlead Nil 20-130 10-60
reasons (mean = 67) (mean =33)
aData ofSmith et al. (97).
1The 41stpatient, notincluded inthesevalues, showed thefollowing concentrations: serum, 30 ,ug/100ml;cells + filbrin,
730 ug/100 ml; whole blood, 410 ,ug/100 ml.
cThe 35th patient, not included in these values, showed the following concentrations: serum, 20 ,ug/100ml; cells + fibrin,
2,290 ZgIl00 ml; whole blood, 830 Isg/100 ml.
"The 18th patient, not included in these values, showed the following concentrations: serum, nil; cells + fibrin, 1,110
,ug/100 ml; whole blood, 640 ,ug/100 ml. This individual was studied 2 mo after the toxic episode.
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time (Fig. 1). The concentrations found for the
"normals" of their Table 4 were said to be essen-
tially independent of sex, age (adults), climatic
changes, daily fatigue, violent exercise, meals,
menstruation and ovulation. Today, with more sen-
sitive methods, we know that meals and perhaps
some other of these factors would affect the con-
centrations of at least PbB.
It is seen in Table 3 that the patients were rated
for their degree of lead symptomology. This was
done using a ranking of the signs and symptoms
collected from nine reports. Smith et al. compared
these changes with change in concentration of PbS
at the time ofthe ratings. Some ofthe patients were
studied for up to 150 days. Three patients died.
Qualitatively, there appears to be an association be-
tween the direction of PbS change and direction of
change of symptomology. The data cannot be con-
sidered quantitatively because of the coarseness of
the symptom ratings and because many PbS con-
centrations were near 10 ,ug/100 ml, their assayable
limit.
In a subsequent report (102) they summarized the
concentrations oflead found in serum, cells + fibrin
and whole blood under normal conditions and in the
"active phase ofacute or chronic toxicity," "latent
phase" and "inactive chronic phase." They also
presented the concentrations for an additional case
studied, along with the leucocyte and erthyrocyte
concentrations of lead.
Table 3. Relationship between change of lead concentration in
serum and change of dinical status.a
Sequence of
Patient serumconcentrations,
NO.b g/jIO ml
1 20,60
2 30, 20, nil
3 nil, 20
4 nil,40, 50, nil
5 nil, 30, 20
6 nil,20, 30, 50, 90, 30, nil
7 10, 50, nil
8 10, 50, 40, 30,nil,nil, 30, nil
9 nil, 50, 20, nil
10 nil,40, 20
11 10,20
12 10, nil, nil
13 30, 20, nil
14 30, 50, nil, nil
15 nil, 30
16 nil, 20, 20, 50, 50
17 30, nil,nl, nil
Sequence of
clinical conditions
Poor, died
Poor, improved, well
Fair, symptoms after
acidification therapy
Good,fair,fair, well
Fair, poor, died
Good,fair, worse, bad,bad,
improved, well
Good,fair, well
Good, poor, improved,
better, well,fair, poor,
well
Good, poor, improved, well
Good,fair, fair
Fair, fair
Fair, good,well
Fair, good,good
Fair, poor, improved, well
Poor, died
Fair, fair, poor, poor, worse
Fair, fair, good,well
More recently, McRoberts (65) was the ap-
pointed doctor for a lead battery factory in the
U. K. He tried to avoid some of the problems of
Smith et al. (97). He drew 6-8 ml of heparinized
blood in lead-free syringes and sent these to the
National Occupational Hygiene Service for
analysis. Other clinical chemistry and hematology
assays were done locally. Of 81 initial blood sam-
ples from 21 men, seven were assayed directly for
PbB and the remainder were centrifuged for
analysis ofthe plasma and cellfractions. Hemolysis
occurred in 20 samples and, therefore, only PbB
concentrations were reported for these (the sum of
the two fractions). In all, there were 54 PbP
analyses for 18 men. Six duplicate random samples
were assayed satisfactorily as a check on precision.
Since a dithizone method was used, the differences
between the very low PbP values may be in ques-
tion.
Five of the 18 men studied were categorized as
having had some of the signs and symptoms oflead
toxicity while, except for transient anemia in some
cases, 13 did not.
The first of the five individuals was occupation-
ally exposed to lead for about a month. PbB and Hb
concentrations over the next 2 mo were: PbB, 510,
790, and 535 ugIl/00 ml; four Hb values were be-
tween 11.7 and 13.2 mg/100 ml. PbU and urine co-
proporphyrin (CPU) assays at the end of2 mo were
low normal. Over this period, several physicians
could not detect clinical signs or symptoms. How-
ever, because of the worker's very high PbB con-
centrations, the decision was made to attempt de-
leading.
On the morning of hospitalization 3 wk later and
the following morning (Table 4), PbP concentra-
tions were, respectively, 16 and 71 ,ug/100 ml, and
PbB concentrations 313 and 295 ,g/100 ml, all quite
high. Occasional stipple cells were noted, and a
slight tremor was detected at this time, though other
clinical and laboratory tests were normal. A test
dose of CaNa2EDTA, less than recommended for
deleading, was administered intravenously over 2
hr. At 4:30 p.m., PbP and PbB were still high, 59
and 297 ,ug/100 ml, respectively. In the evening,
there was an encephalopathic reaction which in-
cluded cardiac and respiratory arrest. Chisolm
warned against this hazard when either too low or
insufficiently frequent doses of CaNa2EDTA are
given (103). PbU tests over several days showed
that 2.6 mg of extra lead was excreted. For 2 days
and at a month after, PbP concentrations were now,
respectively, 6, 3, and 10 ,ug/100 ml while PbB de-
creased but was still in the hazardous range at the
end ofthis time.
A second worker became anemic within 3 mo at
the factory and was then suspended because oflow
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aData of Smith et al. (97).
bIn the report the patients are identified by initials, sex and
type oflead exposure.
272Hb. Twelve PbP concentrations over 2 mo (Table
4) varied from 3 to 8 ,ug/100 ml, with four inter-
spersed values of 12-22 ,ug/100 ml. Over this period,
PbB increased to a plateau and then declined. Hb
remained low for a month and then began to rise
slowly. Over the first month ofsuspension he com-
plained oftiredness and intermittent, vague pains in
the muscles of the arms and legs. Examination
didn't reveal abnormalities.
The third worker was suspended after 7 days be-
cause ofthe low Hb (Table 4). This did not improve
over a month with oral iron therapy. PbP values
were 10, 15, and 4 ug/100 ml over a month while
PbB values were, respectively, 117, 66, and 22
,ug/l00 ml. Only the persistent anemia was present
as a sign, and because ofthis, worker 3 is discussed
furtherbelow.
The fourth worker was away from work because
Table 4. Lead concentrations in the plasma, cells, and whole blood offive lead battery workers with signs
and symptoms oflead toxicity.a
Hb. Pb, ,ug/100 ml
Worker Date g/100 ml Plasma Cells Whole blood Time
1 5/27/69 14.0 16 621 313 11:45 a.m.
5/28/69 71 527 295 9:00 a.m.
5/28/69 CaNa2EDTA, i.v. administration Noon-2 p.m.
5/28/69 59 544 297 4:30 p.m.
5/28/69 Encephalopathic episode 7:25 p.m.
5/29/69 6 583 283 9:00 a.m.
5/30/69 3 500 241 9:00 a.m.
6/23/69 10 272 141
2 7/18/69 10.8 4 138 87
7/19/69 11.4 3 155 84
7/21/69 11.4 22 230 120
7/24/69 11.5 4 253 106
7/26/69 11.4 3 253 106
7/28/69 11.8 3 280 115
7/29/69 11.9 2 280 108
7/31/69 11.4 17 250 118
8/02/69 11.4 16 211 102
8/06/69 11.8 8 223 101
8/09/69 11.0 Hemolyzed 87
8/13/69 11.2 12 203 94
8/22/69 12.0 5 156 78
9/19/69 12.6 Hemolyzed 66
3 12/08/69 11.2 10 279 117
12/16/69 11.6 15 116 66
1/07/70 11.3 4 42 22
4 1/27/70 15.2 16 114 -85
2/24/70 14.9 5 126 67
5 2/05/0 12.6 Hemolyzed 88
2/07 to
2/23/70 Away from work
2/24/70 13.1 6 920 415
3/03/70 12.4 Hemolyzed 381
3/10/70 13.8 Hemolyzed 435
3/13/70 Stopped work
3/17/70 13.5 12 1034 480
3/19/70 10.9 Hemolyzed 515
aData of McRoberts (65). Workers identified by initials in original report.
August 1977 273of "influenza" symptoms (Table 4). Two blood
samples a month apart showed, respectively, PbP,
16 and 5 ,ug/100 ml; PbB, 85 and 67 ,g/100 ml; Hb
was normal. He complained of malaise, weakness
and general aches and pains.
The last worker had a moderate degree ofanemia
(Table 4). However 67% (four out of six) of his
blood samples hemolyzed. This was the highest
proportion observed for the 18 workmen studied.
PbP concentrations 3 wk apart were 6 and 12Ag/100
ml and the PbB values, respectively, 415 and 480
,ug/100 ml. Other PbB concentrations are shown in
Table 4. He complained oftiredness and irritability.
For these five "symptomatic" individuals, then,
the PbP values for 10 out of25 samples were 12-71
,ug/100 ml. Except for the single PbP assay after
CaNa2EDTA, nine of the increased plasma con-
centrations were not associated with pharmacologic
intervention. In one ofthe nine, there was said to be
fever at the time. PbB for 31 samples was 22-515
,ug/100 ml. In addition, there were two PbP con-
centrations of 10 ,g/100 ml, with corresponding
PbB values of 141 and 117 ,ug/100 ml. The first
worker also had PbB concentrations of 510, 535,
and 790 ,ug/100 ml.
The following, now, are the data for the 13 men
who were said to,be nonsymptomatic. The PbP for
28 samples was 1-7 ,ug/100 ml and PbB for 43 sam-
ples was 33-173 ,ug/100 ml, with outlying values of
18 and 250,g/100 ml. There was also one PbP value
of 10 ,g/100 ml, with the corresponding PbB value
of82 ,zg/100 ml.
Closer examination of the data shows that either
"symptomatic" worker 3 could have been moved
to the nonsymptomatic group because he had only
anemia for the 1 mo that he was followed, or four
workers classified as "nonsymptomatic" could
have been considered symptomatic on the basis of
their "transient" anemia. Another three "non-
symptomatic" workers were not studied long
enough to say whether their borderline anemia was
transient or persistent. The choice can be made
more easily to transfer worker 3 to the nonsymp-
tomatic group because transient versus persistent
anemia is a quantitative issue and his relatively low
PbB concentrations supports the assignment. While
these considerations call attention to a weak point,
itdoes noteliminate the pattern found.
Therefore, although the increase of PbP in the
group of five (or four) workers occurred in only
about one-third of the samples, the most striking
difference between the groups was that this differ-
ence occurred. McRoberts (65) suggested that a
PbP of about 10 ug/100 ml might be the dividing
area between asymptomatic and symptomatic
states.
He wrote: "most recent work has been con-
cerned with the establishment of biological criteria
to confirm the diagnosis oflead poisoning, and this
is of the utmost importance in the preventive as-
pects ofindustrial medicine, but there appears to be
a place for continuing research into the biochemical
or biophysical trigger mechanism which induces a
state of intoxication. Further investigation into the
part played by 'lead integration' [McRobert's term
for the binding of lead in erythrocytes and perhaps
in soft tissue cells] and the reasons for its failure
may afford an opportunity to develop new
therapeutic measures." And unfortunately, "al-
though the estimation of the plasma lead fraction
mightgive presumptive evidence ofimminentintox-
ication, technical difficulties preclude its use as a
routine test."
Tissue Effects
Enzymes, Intermediates, and End-Products
Assay for enzyme activity, intermediates, and
end-products, incorporation of precursor mole-
cules, concentration of compounds along shunt
pathways or otherwise abnormal products, and rate
of excretion or secretion are used extensively to
assess subclinical and clinical reactions. The aim
here is to preclude or reduce illness in the following
ways: (a) detection ofreversible stages ofabnormal
tissue function, when these are present, in order to
avoid the irreversible effects; (b) identification of
hyperreactive individuals or population groups,
whether the hyperreactivity is due to genetic, nutri-
tion, occupational, regional or other factors; (c) de-
termination of hazardous combinations of expos-
ure, where neither alone may be of particular
hazard.
Tissues that are affected by lead absorption in-
clude the hemopoietic system, central and
peripheral nervous systems, kidney, gastrointesti-
nal tract, skeletal muscle, liver, immune system,
reproductive system, and cardiac muscle. Most
biochemical and physiologic tests so far have as-
sayed aspects of hemopoiesis and also the mature
erythrocyte. There are many fewer biochemical
studies for the nervous system and the kidney, and
improved tests are greatly needed for these. Tests
that operate in the region ofthe critical and subclin-
ical effects are, ideally, what are desired. Effects
below these may be indicative of exposure, though
not particularly of hazard, while effects at and
above these levels should be responded to with
more concern.
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Dose-effect and dose-response relationships
were discussed recently with regard to the clinical
and epidemiologic aspects of lead absorption (15,
16, 104, 105). When the law ofbiologic random var-
iation applies, the dose-effect and dose-response
curves have the samegeneral form.
Dose-effect assesses quantitative change in en-
zyme activity, concentration of a metabolite or
specific function for an individual. It is the most
used relationship for a pharmacologic or toxicologic
reaction. Test results that indicate an abnormally
high or low value, either without concurrent symp-
toms or with symptomology, respectively, have
been designated false-positives and false-negatives.
Dose-effect does not initially recognize the "reac-
tors" and "nonreactors" who are two or three
standard deviations from the mean. Individuals can
vary also with regard to the threshold, slope, and
maximum effect of their effect curves. The
threshold or no-effect level is, actually, a practical
no-effect level, below which the difference from
zero cannot be distinguished for a variety of
reasons.
Dose-effect assumes either that we know the
concentration of a toxic agent at the site of action,
usually not the case, or that, for example, blood or
urine concentration is an accurate indicator of the
"internal dose" at the reactive site. Occurrence of
transient, rather wide variations of PbB were al-
ready discussed. Chisolm states "though it is pos-
sible that this assumption may be ofsome use under
carefully controlled steady-state conditions, it is in-
creasingly evident that it is not valid in the highly
unstable epidemiologic circumstances under which
childhood plumbism actually occurs (15)."
Dose-response, also called dose-percent, relates
to the proportion of a group or population that re-
sponds to a defined extent for a particular effect.
Dose-response is useful in clinical and
epidemiologic investigations. It identifies the reac-
tors and nonreactors. Accurate dose-response
curves are dependent upon the size and selection of
the group.
Zielhuis (105) suggests that "because literature
data do not yet cover large groups of exposed sub-
jects, one should not try to approach zero-% too
closely, e.g. 0.1, 1.0%; one should use about 5%.
Thus, one can estimate a practical non-response
level, i.e. not inducing a specific intensity of a
specific parameter [more than] in 5% of the sub-
jects." The finding ofa value more than the mean +
2 or 3 SD for an individual would classify the indi-
vidual as a reactor, subject to confirmation.
Biochemical tests forlead absorption and toxicity
have been reviewed often (15, 32, 49, 89, 96, 99,
104-109). Some of this information will be pre-
sented along with newer information, as it relates
particularly to effects withthe low lead exposures.
Hemopoiesis and Mature Erythrocytes
Inhibitory effects on Hb synthesis in the eryth-
roid cells of the bone marrow is a "critical effect"
of lead, since this is a reversible adverse effect at
the lowest doses so far determined, preceding sig-
nificant renal injury and clinically evident
neurologic manifestations (15, 16, 18). The im-
mediate results of the interference are the accumu-
lation of a variety of intermediates. Further effects
at higherconcentrations include those on the degree
ofprogression ofthe stages ofmaturation ofthe red
cells, effects on globin synthesis, and effects on the
morphology and stability ofthe cells (32, 49, 89, 96,
104, 105, 109). These effects can have several con-
comitants: (a) functional deficits are proposed to
ensue in primary or secondary relationship to the
extent ofthe effects, (b) the effects may be apredic-
tor ofrelated or unrelated effects occurring in other
tissues, and (c) at the earlier stages, it may be
primarily an appropriate sentinel, prior to the oc-
currence ofmore hazardous responses.
The sequence of conversion from the reaction
of glycine with succinylcoenzyme A to the com-
pleted heme molecule has long been a subject of
study and was outlined recently (110-112). The
points ofknown and suspected interference by lead
are noted (99). Some of the intermediates are, se-
quentially: 8-aminolevulinic acid (ALA, the alipha-
tic addition product ofglycine + succinylcoenzyme
A), porphobilinogen (PBG, a pyrrole formed by
cyclization and loss of H20), uroporphyrinogin III
(UPG, believed to be the first cyclized tetrapyrrole
in heme synthesis), coproporphyrinogen-IIl (CPG),
protoporphyrinogen IX (PPG), and protoporhyrin
IX (PP). The final step is insertion of Fe2+. The
tetrapyrrole "ogen" compounds are all colorless
and nonaromatic and are rather easily oxidized to
the aromatic porphyrins.
The usual compounds and media that have been
assayed for an effect of lead absorption are:
8-aminolevulinic acid dehydrase (ALAD, the en-
zyme that converts ALA to PBG, and which is
present in erythrocytes and in other tissues),
8-aminolevulinic acid (ALA, in urine); copropor-
phyrin III (CP, the oxidized product from CPG,
excreted in urine); and protoporphyrin IX (present
in erythrocytes and usually assayed in the whole
blood). The other compounds and enzymes in the
sequence have been studied with regard to genetic
August 1977 275porphyrias and photosensitization reactions, less so
with regard to lead hazard.
Zielhuis' Overview. Zielhuis (105) reviewed and
suggested the following PbB concentrations as the
non-response (< 5%) levels for the parameters indi-
cated. In some cases, the PbB concentration for
greater degrees ofeffect were also estimated.
ALAD. No-response (no inhibition) level, about
10 Ag Pb/100 ml; >40% inhibition in adults, 15-20
,ug/100 ml and in chilren, 5-10 ,g/100 ml; >70%
inhibition in adults, 25-30 ,g/100 ml and in children,
20-25 ,ug/100 ml.
PPE (FEP). Erythrocyte protoporphyrin and free
erythrocyte protoporphyrin are used interchange-
ably here. No-response in adult males, 25-30 ,ug
Pb/100 ml and in adult females and children, 20-25
,ug/100 ml.
ALAU. No-response for urinary excretion of
ALA > S mg/l, 30-40 ug Pb/100 ml; > 10 mg/I,
40-50 ,ug/l00 ml.
CPU. Urinary excretion ofCP is about the same
as for ALA, but there appears to be some evidence
that the PbB concentrations will be lower for
women.
Hematologic Effects. Preliminary evidence is
cited for inhibition of erythrocyte membrane
Na+K+ATPase and for the reduction oferythrocyte
concentration of GSH. The slope of the dose-
effect curve for Na+K+ ATPase is small. For
Na+K+ATPase activity < 40 ,umole PJ/hr/mg
tyrosine, 20-29 ,tg Pb/100 ml; for GSH < 58 ,g/100
ml of erythrocytes, 25-30 ,ug/100 ml. Anemia (de-
creased Hb) does not occur in otherwise healthy
adults below 70-80ixg/100 ml, and in socioeconomi-
cally poorchildren below 40-50,g/100 ml.
OtherEffects. No-response levels for other ef-
fects are also given. Other biochemical parameters
(a mixed, nonhemologic group that includes effects
on 5-hydroxyindolacetic acid, uric acid, bilirubin,
serum glutamic oxaloacetic transaminase and pyru-
vate) the no-response level is said to be at least
50-60 ug Pb/100 ml. For subjective symptoms the
no-response level is > 50 ,ug Pb/100 ml. No-
response level for encephalopathy is >> 80 ug
Pb/100 ml in adults and > 50-60 ,ug/100 ml in chil-
dren. For minimal brain dysfunction, the no-
response level is > 40-50 ug Pb/100 ml; for
peripheral neuropathy, > 40,g/100ml; forlate clin-
ical sequelae (also mixed, nonhemologic groups of
many types of diseases), at least 40-60 ,ug Pb/100
ml.
Zielhuis (105) stresses that the words "effect"
and "response" are neutral in that they do not
imply a deleterious effect on health, nor does it
necessarily correspond to "unacceptability." Thus,
while minimal to moderate inhibition of ALAD is
acceptable in the absence ofother lead hazard find-
ings, some of the others would clearly not be ac-
ceptable and others would constitute cause for con-
cern and protective action. This is not in distinction
to Chisolm's description ofthe "critical effect" and
"critical site" concepts, since the critical effect is
the first measurable adverse effect, not necessarily
the most serious one (15).
ALA, PBG, UP, and CP. The concentrations of
PBG in urine and UP (uroporphyrin) in blood and
urine are only slightly affected, if at all, in lead
poisoning (49). The excretion ofALA in urine with
some studies in serum, and excretion ofCP in urine
(though the latter is present in much lower concen-
tration in blood but much higher concentration in
feces), have been among the earliest and longest
studied parameters of heme synthesis. Thus, a
statement by 18 individuals (106) divided lead
poisoning into three stages above the normal state
and presented what they agreed upon as appro-
priate concentrations of ALAU (8-aminolevulinic
acid in urine) and CPU (coproporphyrin in urine),
PbU, and PbB. For the normal situation and the
''acceptable," "excessive," and "dangerous"
categories of exposure, their appropriate ALAU
concentrations were, respectively, <6, 6-20, 20-40
and > 40 mg/I; CPU concentrations were, respec-
tively, < 150, 150-500, 500-1500 and > 1500 ug/I.
Browder et al. (32) state that lead poisoning
should be considered when the following concentra-
tions are found: ALAU, 5 mg/24 hr in children and
10-20 mg/l for industrial workers (113); CPU > 150
,ug/24 hr in children and > 200 4g/24 hr in adults
(114). Baloh (99) pointed out that the tests for
ALAU and CPU in children are subject to high
rates offalse positive and false negative determina-
tions and, for this reason, are much more useful in
industry where PbB may be above70-80,ug/100 ml.
Among the data reviewed, Baloh quoted the exten-
sive findings of Stankovic (115) in industrial work-
ers. Stankovic (115) reported the following concen-
trations for the normal, "slight," "moderate" and
"severe" categories respectively: ALAU, < 4.5,
<10, >10, >20 mg/I; for CPU, <90, <180, >180
and >700 1ug/. In small children (116), the upper
normal forCPU was 75 ,ug/24 hrandforadults (117,
118), 250 ug/24 hr. Baloh suggested that because of
the considerable variability ofurine output, a better
value of upper normal for both children and adults
is, perhaps, 200 ,ug/l (119). Chisolm (15) also pre-
sented data for ALAU in children and expressed it
in units of mg/m2/24 hr. Most of the data in this
report were recalculated from previous work.
Benson et al. (50) determined PbB, ALAU, and
CPU changes in men after first starting work at a
lead pigment factory and at weekly intervals for up
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of Tola et al. (19), who also studied initial ex-
posures. Hb remained at >13 mg/100 ml and there
were no clinical symptoms. The preemployment
PbB concentration was about 22 ,g/100 ml. It rose
by I wk and reached 60 ,g/100 ml by 3 wk and then
stabilized. The changes in ALAU and CPU corre-
lated well with one another and for most subjects,
ALAU and CPU did not increase in the first 2 wk.
Then there was a variable response. In a group of
nine, the increase occurred over a period of 3-4 wk
followed by variable increases afterward. In a
group of six, there was a muted response, with
small change for both parameters over the entire
time period. For two individuals, there was an ex-
aggerated response by 2 weeks. There were some
striking differences between individuals, which was
felt to be the major finding made. It was suggested
that different monitoring methods might be appro-
priate for the initial period ofexposure as compared
to later, when the individuals become more stabi-
1ized.
ALAU is one of the most specific indicators of
lead toxicity, particularly in children. Only acute
alcoholic intoxication and the genetic condition,
acute intermittent porphyria, cause significant ele-
vations of ALAU. CPU is less specific. It can be
increased in rheumatic fever, poliomyelitis, infecti-
ous mononucleosis, alcohol intoxication, cirrhosis
ofthe liver, acute toxic hepatitis, acute intermittent
porphyria and iron deficiency anemia (32, 99).
ALAD and EP. ALAD is the second enzyme,
after 8-aminolevulinic acid synthase, in the synth-
esis of porphyrins from glycine and succinylcoen-
zyme A. It catalyzes the synthesis of PBG. When
inhibited, 8-aminolevulinic acid should accumulate
if the enzyme is not in excess. There are many re-
ports which indicate that erythrocyte ALAD inhibi-
tion is very sensitive to lead concentration, even
down to a PbB of 10-15 ,ug/100 ml and sometimes
less (99, 104, 120). The enzyme is activated (120) by
low concentrations of Hg2+, Cd2+, and EDTA and
inhibited by higher concentrations ofeach of these.
lt is activated by the sulfhydryl compounds
glutathione, cysteine, dithiothreitol, and mercap-
toethanol as well as by Zn2+. Activation by the
sulfhydryl compounds and by Zn2+ are additive,
suggesting that activation occurs by different
mechanisms. Zn2+ counteracts both the activation
and inhibition caused by EDTA. EDTA and other
chelating agents should be avoided in vivo if ALAD
is to be assayed and fresh or cold-stored blood
should be used for the assay.
The enzyme activity can be determined directly
as PBG synthesis or as the ratio of activated to the
nonactivated preparation. Genetic factors ac-
counted for no more than a twofold variation in
ALAD in this study (120). Elsewhere it has been
shown that the enzyme can also be activated by
heating to 60°C for 5 min (121), that genetic factors
may contribute a rather large effect at low concen-
trations of lead (122), that acute alcohol ingestion
can inhibit the enzyme activity but that activity is
restored as the blood alcohol concentration declines
(123) and that the enzyme from Rhodo-
pseudomonas spheroides is inhibited by proto-
porphyrin and hemin (124).
ALAD was assayed in blood, brain, and liver of
rats that received lead from birth, first via milk from
lactating rats fed lead acetate in their feed, and then
also from the feed, itself. By 30-40 days, blood and
brain ALAD were inhibited by 80-90% and liver
ALAD by 66% (125). In 22-day-old male rats ex-
posed to three doses of lead via the maternal milk,
ALAD was inhibited in a dose-dependent manner
in erythrocytes and in the cerebellum. It was inhib-
ited only at the highest dose in the telencephalon
and brainstem. Sobotka et al. (124) suggested that
the enzyme activity in these three brain regions
might be due to residual blood, though little blood
should have been present (126). Secchi et al. (127)
showed that human liver ALAD is inhibited by
lead. Wada et al. (128) demonstrated reduction of
activity of ALAD and heme synthase (fer-
rochelase), and a reduced incorporation of
14C-glycine into the heme and globin of erythroid
cells of the bone marrow in workers that had PbB
concentrations of 40-90 ,g/l00 ml.
The relevance of the ALAD test with blood was
questioned on several bases: (a) the enzyme ap-
pears to be vestigial and plays no known role in the
mature erythrocyte, (b) an excess of the enzyme is
present, and (c) no decrement in biologic function is
known at the lower end of the scale to relate to the
decreased values (104). The test detects both acute
and chronic lead poisoning and there is no lag, in
*i}ho, in inhibition of ALAD after exposure to the
lead. The test is not positive for iron-deficiency
states (129). It was suggested that the test can be
used at the lower end of the inhibition curve, at
least as a sensitive indicator of apparent exposure
to lead, though apparently not with regard to
hazard.
The history of the clinical relevance of protopor-
phyrin (130) and porphyrins in general (131) is long.
However it has mainly been in the last few years
that this factor, in two major public health problem
areas-lead hazard and iron-deficiency anemia-
has received more than a minor amount ofattention
in comparison with the genetic porphyrias. Iron-
deficiency conditions have been subdivided into
those due to: insufficient iron intake, malabsorp-
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the iron (130). Other disorders can also occasionally
account for the accumulation of protoporphyrin in
the erythrocyte. These are: hemolytic anemia,
sideroblastic anemia, anemia associated with
chronic disease, and secondary polycythemia. The
free erythrocyte protoporphyrin test (FEP) has also
been suggested as an aid for differentiating the mild
anemia and microcytosis seen in alpha and beta
thalassemia trait due to iron deficiency anemia
(131).
More than 95% ofthe prophyrin that accumulates
in the erythrocyte following absorption of lead and
in the genetic condition, erythropoietic protopor-
phyria (EPP), is protoporphyrin IX (EP) (132). This
is also the case in iron deficiency anemia (133). In
both lead absorption and iron deficiency, it is the
Zn chelate of protoporphyrin that accumulates
(133, 134) while in EPP it is mainly the free, basic
form of protoporphyrin (134). The Zn chelate is
bound to the heme site on hemoglobin, while the
basic form is bound to nonheme sites (134). Acidic
organic solvents are used to extract "free" erythro-
cyte prophyrins (free ofthe Zn), while the intact Zn
chelate can be extracted with acetone, ethanol or
the detergent Ammonyx-LO (134). Some of the
quantitative tests used for protoporphyrin assay ex-
tract nearly all of the porphyrins, while a few ex-
tract much smaller quantities. Tests that extract
small amounts are often very sensitive to modifying
conditions of many types and, therefore, these lat-
ter cannot usually be counted upon.
Photosensitivity is usually not a complication fol-
lowing lead absorption despite the presence of pro-
toporphyrin in the erythrocytes to a concentration
that can be equal to or greater than that found in
EPP. In lead absorption, the erythrocyte Zn pro-
toporphyrin concentration declines only slightly, if
at all, as the erythrocytes age. In EPP, however,
the protoporphyrin declines rapidly as the erythro-
cytes age (a lifetime about 3 days). Incubation of
the erythrocytes in plasma showed rapid diffusion
of EP into the plasma in the case of EPP but not
after lead absorption. In vivo, plasma EP was also
elevated in EPP but not in lead absorption. These
findings were used to explain the migration of pro-
toporphyrin into cutaneous tissue in EPP, which
then results in photosensitivity. This does not occur
in the case of lead absorption (135).
A variety oftests were developed for the assay of
EP (these tests are usually referred to as EP, FEP,
and occasionally PP or PPE; (99, 104, 133,
136-139). Contrary to the ALAD assay, for which
there is no time lag and which can detect acute ex-
posure to lead, FEP change occurs in the bone mar-
row. The cells are released to the peripheral circula-
tion as they mature and, thus, there is a lag in the
increase of peripheral blood FEP. Because FEP
stays with the erythrocytes through their lifetime,
its assay detects a chronic effect.
Sassa, et al. (136) showed a plot of FEP concen-
trations for children at PbB concentrations of20-80
,g/100 ml and obtained a correlation coefficient of
0.72, which is close to that obtained by others.
When they replotted the data utilizing only children
who were known to have essentially constant PbB
for at least 3 mo, the correlation coefficient in-
creased to 0.91. They also assayed FEP along with
ALAD and uroporphyrinogin synthase (URO-S;
for other of their studies) in nine pair of twins.
Monozygosity was established by extensive blood
group testing for four pair (136). The concentrations
for twin pairs, were close in most cases for each of
the parameters, suggesting a genetic component, as
well, in the control of the amount of enzyme activ-
ity. There was a two- to threefold spread of values
for FEP, fourfold for ALAD, and threefold for
URO-S.
Penny et al. (161) compared PbB, ALAD, and
FEP in eight pairs of monozygotic and seven of
dizygotic twins. The intraclass correlation coeffi-
cient differences between mono- and dizygotic
twins were significant for PbB (p < 0.01) and for
FEP (p < 0.05). The difference for ALAD was not
significant.
Landrigan et al. (141) studied children aged 1-9
yr at various distances from a lead smelter. PbB
concentrations were remarkably high. Within 1.6
km of the smelter, 99% of 172 of the children
studied had PbB ¢40 ,g/100 ml and 22% had ¢80
,ug/l00 ml; PbB, as expected, decreased with in-
creasing distance from the smelter. The usual
logarithmic increase of FEP with increasing PbB
concentration, as obtained by others, was also ob-
tained here. Roels et al. (142) studied 143 children
ages 10-15 yr as well as adult men and women near
a lead smelter and in a rural area. In this study, PbB
varied from 5 to 41 ,mg/100 ml for all ofthe children.
They found that the inhibition of ALAD was most
sensitive, to changes of PbB, FEP was almost as
sensitive and there was a considerably lesser re-
sponse for ALAU. The dose-response relation-
ships obtained for the children were as follows (for
each PbB group vs. the percent of ALAD and FEP
values, respectively, ofgreater than the mean value
+ 2 SD): for 59 children with PbB < 10 Ag/l00 ml,
ALAD 3.4% and FEP 1.7%; for 41 with 10-19.9
gg/100 ml, 7.3% and 9.8%; for 24 with 20-29.9
,g/l00 ml, 67% and 46%; for 17 with 30-39.9 ,ug/l00
ml, 100% and 88%; for two with 40-49.9 pkg/l00 ml,
100% and 100%. They found, in addition, that chil-
dren were most sensitive to FEP alteration, women
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Klein et al. (143) presented data for 1523 analyses
on children who were all presumably under 5 yr of
age. They reported the dose-response data for the
percent ofchildren in each combination offive PbB
and two FEP groups: 490 children with PbB < 30
,g/100 ml and FEP >60 AgIl00 ml, 8% or FEP
>190 ,g/100 ml, 0.2%; 562 children with PbB 30-39
tg/lg0 ml and FEP >60 Ag/l00 ml, 22% or FEP
>190 yg/100 ml, 1.0%; 267 with PbB 40-49 ,g/100
ml and FEP >60 ug/100 ml, 45% or FEP >190
,ug/100 ml, 4.5%; 109 with PbB 50-59,ug/100 ml and
FEP >60AgI100 ml, 54% and FEP >190Ag/l00 ml,
16.5%; 95 with PbB >60 ig/100 ml and FEP >60
AgI100 ml, 72% or FEP >190 Ag/l00 ml, 26.3%.
Reigert and Whitlock (144) conducted a time-
course analysis for 349 children with regard to PbB
and FEP concentrations. They confirmed the find-
ing of Sassa et al. (136) that change in FEP repre-
sents a long-term and relatively stable effect. They
wrote: "Short- and long-term comparison of the
variations with time of whole blood lead and free
erythrocyte protoporphyrins (FEP) suggests that
changes in FEP are slow and predictable whereas
blood lead changes are quite unpredictable. How-
ever, when FEP suggests a different clinical cate-
gory from blood lead, the blood lead is likely to
change in the direction predicted by the FEP.
Comparison ofFEP to blood lead at first contact in
349 children with mild elevation of blood lead reli-
ably predicted which children would still have ele-
vated blood lead six weeks later and which would
fall or be normal. The observation of long-term
follow-up in four groups of children with various
combinations of FEP and blood lead indicated that
the follow-up blood lead could be predicted to
change in the direction indicated by the FEP mea-
surement. "
Chisolm (15) found that FEP is a sensitive indi-
cator of the "internal dose" of lead as long as iron
deficiency and its concomitant anemia were
mathematically corrected by adetermination ofHct
or Hb. "In children with hematocrit :36% and PbB
<30,ug/100 ml, we have found thaterythrocyte pro-
toporphyrin levels are low and independent of PbB
concentration ... ¢90% of children with PbB ¢50
,tg/100 ml are positive reactors and that 50% re-
sponse rate is associated with PbB in the 40-50
,ug/100 ml range (15)." Elsewhere (89) it is stated
that "significant numbers of children with blood
lead levels of30-39 ,ug/100 ml have shown evidence
of metabolic impairment as detected by EP test-
ing."
The values obtained in the FEP test are depen-
dent upon the method used. Some standardization
is now coming into this area. The FEP test is posi-
tive (+3 SD above the mean) when it is >60 ,tg/l00
ml by the ethyl acetate, acetic acid, HCI extraction
method (89). Piomelli (138) gives the equivalent
values in other units: >5.3 ,ug/g Hb and >160
,ug/l00 ml of packed erythrocytes.
The Center for Disease Control published rec-
ommendations (89) for: (a) screening for lead ab-
sorption in children, (b) diagnostic tests after
screening if this is indicated, (c) pediatric manage-
ment where absorption or poisoning is found and
also with regard to preventive retesting of "nor-
mals," (d) hazard control, (e) education of parents
of children who are at risk, and (f) the reporting of
detected cases of lead absorption or poisoning.
They defined undue or increased lead absorption
as: "confirmed [two successive determinations]
blood lead levels 30-79 ,ug/l00 ml or an EP [FEP]
level of60-189 ,g/l00 ml except where the elevated
EP level is caused by iron deficiency." They de-
fined lead poisoning in children as the existence of
(a) a confirmed blood lead equal to or greater than
80 ,ug/l00 ml whole blood with or without symp-
toms, (b) EP level equal to or greater than 190
,ug/100 ml whole blood with or without symptoms,
(c) confirmed blood lead 50-79 ,ug/l00 ml with com-
patible symptoms which cannot be explained
otherwise or with associated abnormal EP, ALAD,
ALAU, or CPU levels or abnormal calcium di-
sodium EDTA mobilization tests, or (d) EP level of
110-189 ,ug/100 ml with compatible symptoms which
cannot be explained otherwise. Toxicity, overall,
with respect to effects of lead in children, includes
subclinical manifestations of biochemical derange-
ments (such as increased EP) as well as overt
clinical manifestations (such as encephalopathy,
Fanconi syndrome, etc.)
Table 5 depicts their grouping of the four classes
from normal to the extremely elevated state with
regard to the lead and EP values. For example, it is
stated that "although the EP standard is based on
tests involving several tens of thousands of chil-
dren, this experience is more limited than that as-
sociated with blood lead. There may be need for
revision of these standards when increased experi-
ence with EP measurements becomes available."
And, "the suggested guidelines refer to the in-
terpretation of screening results, but the final diag-
nosis and disposition rest on a more complete medi-
cal and laboratory examination of the individual
child." Additional diagnostic tests and pediatric
management are discussed. The report gives an in-
dication of the thinking applied to differential diag-
nosis and relative risks for lead hazard.
The PbB and EP concentrations of each Class
are shown in Table 5. In Table 6, class I is sub-
divided into classes Ia and lb. Class Ia includes
August 1977 279Table 5. Classification of normal and elevated concentrations of
lead and erythrocyte protoporphyrin in whole blood."
Pb, ,ug/l00 ml
EP, tLg/100 ml
Class I
normal
-s 29
59
Class II
minimally
elevated
30-49
60-109
Class III
moderately
elevated
50-79
110-189
Class IV
extremely
elevated
¢ 80
190
'Data of Center for Disease Control (89).
Table 6. Classiflcation of lead toxicity in children based upon Pb
and EP Blood concentrations."
Class'
Pb level, EP EP EP EP
,g/l00 ml 59 ,Lg 60-109 Ag 110-189 gg
- 190,ug
29 1 Ia Ia EPP+
30-40 lb 11 1111 IV
50-79 * I 11 Ill T IV
80 * * * IV
"Data of Center for Disease Control (89).
"EPP+-Erythropoietic protoporphyria; (*) = combination of
results is not generally observed in practice; when blood lead is
repeated, the results will generally indicate contamination ofthe
first specimen; I denotes downgrading of the estimate of risk of
lead intoxication suggested by blood lead, altered on the basis of
the EP results; T denotes upgrading ofthe estimate ofrisk oflead
intoxication suggested by blood lead, altered on the basis of the
EP results.
children with an apparent effect on EP due to the
lead, but with a transient or error-caused low lead
value. In some cases the increase of EP will be due
to iron deficiency anemia. This can be confirmed as
described (145) and recovery from both the anemia
and the increased ED by successful uptake and
utilization of an administered iron preparation. EP
can increase to as high as the 110-189 ,tg/l00 ml
level in iron deficiency anemia. It must also be kept
in mind that both iron deficiency anemia and in-
creased lead absorption may coexist.
Category lb represents a possible downgrading of
the relevance to lead toxicity since it may be that
there was a transient increase of PbB or a contami-
nated sample. Class II is possibly downgraded in
relevance when the lead is 50-79 Ag/I0O ml for the
same reason. Repeated or further diagnostic tests
are advisable.
Class III and Class IV are potentially upgraded
in relevance when the PbB is <49 ,Ag/l00 ml and
<79 ,ug/100 ml, respectively. This is so since the
PbB determination may be abnormally low for the
reasons stated above. Reassay or further diagnostic
tests are in order.
The following combination is pathognomic for lead
poisoning: (a) decreased ALAD in circulating
erythrocytes, (b) increased ALAU, (c) increased
CPU, and (d) increased FEP (16), though they may
not all occur in a specific case.
If EP is ¢a190 ugIl/00 ml and PbB is -29 ,Ag/l00
ml, this often indicates erythropoietic proto-
porphyria.
Recent EP Associations. Increased FEP,
sometimes > 190 ,tg/I00 ml, is now being seen in a
small number of children other than in relation to
iron deficiency, lead exposure, or the genetic condi-
tion erythropoietic protoporphyria (Chisolm,
Reigart, personal communications). These may re-
flect other genetic (136, 140), nutritional, or other-
wise environmental (69, 146) differences in iron ab-
sorption, transport, or utilization (130) or, perhaps
other mechanisms, for example, affecting the
biosynthesis or utilization of porphyrins more di-
rectly. An association is also being observed
between another particular genetic aberration, sickle
cell disease (SS), double hemoglobin heterozygosity
(SC), and possibly sickle cell trait (SA) and an in-
crease of FEP (Chisolm, personal communication).
There are at least 16 cases of an association in chil-
dren of increased PbB with peripheral neuropathy,
a rare symptom in children (147-149), and among
these there are six cases of SS and one of SC dis-
ease (147-151). The remaining nine cases of
peripheral neuropathy were reported between 1922
and 1952 and the molecular basis of the
hemoglobinopathies was first reported in the late
1940's. Possible causes for the associations are dis-
cussed (147, 148). Further, individuals with the
hemoglobinopathies generally survive to adulthood.
An association between some adult cases of hemo-
globinopathy and some of the indices of lead hazard
should occur.
Other Tissues
Lead is known to affect a variety of other tissues
and, while the clinical and some physiologic aspects
have been described, investigations at the biochem-
ical level are less advanced than for hemopoiesis.
Much is available, though, that cannot be reviewed
here. The kidney and the nervous system have re-
ceived considerable attention. The following reviews
are some that are useful (1, 16, 32, 96, 152-154). A
few recent references will introduce some aspects of
the actions oflead on the tissues: liver (155), kidney
(156-158), and nervous system (126, 159-165).
Clinical Sequelae of Lead Toxicity
The clinical diagnosis oftoxicity due to lead is not
always easy. It is made partly on the basis ofsubjec-
tive and objective symptoms, a variety of signs,
Environmental Health Perspectives 280biochemical analyses, accumulation or excretion of
metabolic products, and evidence oflead exposure.
Individuals may be asymptomatic or symptomatic,
manifesting a wide variety of symptoms, and be in
varying states ofhazard (32). Goyerand Rhyne (153)
point out that "the onset oflead toxicity, even acute
toxicity, is not a sharply defined event. Rather, it
involves a continuum of change from normalcy to
ill-health."
Smith, et al. (97) ranked the many signs and
symptoms of lead toxicity in adults. He added the
caveat, "It should be remembered that all of these
symptoms will never be found in any single case
and frequently a patient is presented for observa-
tion or treatment whose past history to lead expos-
ure would cause one to expect symptoms conform-
ing to group II or III [greater effects] when only
those of group I [lesser effect] can be demon-
strated." Lane etal. (166) gave the following list for
adults of mild symptoms and signs: tiredness, las-
situde, constipation, slight abdominal discomfort or
pain, anorexia, altered sleep, irritability, anemia,
pallor, and less frequently diarrhea and nausea. The
presence ofa blue line in the gums and ofa metallic
taste are useful indicators ofincreased lead absorp-
tion. Severe symptoms and signs include severe in-
termittent abdominal pain (colic), reduction ofmus-
cle power-for example wrist drop, muscle tender-
ness, paresthesia, and other symptoms or signs of
neuropathy or encephalopathy. Dagg et al. (167)
gave a shorter list for adults, in descending order of
frequency of the presenting symptom: abdominal
pain, constipation, vomiting, nonabdominal pain,
asthenia, paresthesia, psychological symptoms and
diarrhea.
The signs and symptoms in children are some-
what different than in adults. For example,
peripheral neuropathy is more common in adults,
while encephalopathy is much more common in
children (153). The following are seen in children
(89); irritability, vomiting, abdominal pain, ataxia,
anorexia, behavioral changes, speech disturbances,
seizures, intercurrent feverand dehydration.
The symptoms in descending order of frequency
in children as listed by Sachs et al. (82) are as fol-
lows: drowsiness, irritability, vomiting, gastroin-
testinal symptoms, ataxia, stupor andfatigue.
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